Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

202255 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: Nature Medicine

Volume 28, Issue 10, pp. 2092-2099

Field-Weighted Citation Impact: 11.55